Sean Emerson George , , Ph.D. , , Chief Executive Officer and Co-Founder

Sean leads the Invitae team on its mission to bring genetic information into mainstream medicine to help improve healthcare for billions of people. A co-founder of the company, Sean has also served as Invitae’s president and chief operating officer, as part of the team that has propelled Invitae from early stage startup to a leader transforming the industry. Sean has long advanced the transformation of the genetics industry to increase access to help improve patient care. Before Invitae, he served as COO at Navigenics, an early pioneer in personalized genetics. Prior to that he served in a variety of product, operating and commercial roles at Affymetrix, Invitrogen and Molecular Probes. Following his graduate work, Sean was a consultant at McKinsey & Co serving in the biopharmaceutical and corporate finance practices. Sean holds a B.S. in Molecular Genetics from UCLA, an M.S. in Molecular Biology from UC Santa Barbara, and a Ph.D. in Molecular Genetics from UC Santa Cruz.

Lee Bendekgey , , , Chief Policy Officer

Lee leads Invitae's payer relations, policy and government affairs, regulatory and QA compliance functions, focused on making the company a trusted partner and advocate for patients, healthcare providers, and payers. Previously, Lee has served as both Invitae's chief operating officer and chief financial officer. He has led finance, administrative, and operations functions at public and private genomics and biotechnology companies, including Incyte, Nuvelo, and DNAnexus. Lee earned his B.A. from Kalamazoo College and his law degree from Stanford Law School.

Tom Brida , , , General Counsel, Chief Compliance Officer and Secretary

Tom leads the legal and compliance team at Invitae. Tom has a broad-based legal background in the life science and diagnostic industries, having advised both public and private multinational companies on transactional​​ and corporate matters. Prior to joining Invitae, Tom served as associate general counsel at Bio-Rad Laboratories and associate in Orrick's corporate and technology group. Tom holds a B.A. from Stanford University and a law degree from U.C. Berkeley School of Law.

Michele Cargill , , Ph.D. , , Co-Founder, Key Projects and Advisor to the CEO

Michele is a co-founder of Invitae and leads projects that advance the company’s offerings and serves as advisor to the CEO. As part of the team that has propelled Invitae from early stage startup to a leader transforming the industry, Michele has driven Invitae’s ability to bring advanced medical genetics to improve patient care. She has more than 17 years of experience as a human geneticist including work in both industry and academia, with a primary interest in discovering the genes that contribute to human disease and translating that information for patients and medical care professionals. Prior to Invitae, Michele served as vice president of genetics at Navigenics and associate director of genomic collaborations at Affymetrix. She also served as senior staff scientist at Celera Diagnostics and scientific program manager at Celera Genomics. She trained under the tutelage of David Botstein at Stanford Medical School, where she earned her Ph.D. in genetics, and Eric Lander at the Whitehead Institute, where she completed her postdoctoral training.

Sandra Close , , Ph.D. , , Chief Diagnostic Strategy Officer

Sandra leads Invitae’s diagnostic strategy efforts on the oncology team having joined Invitae through the acquisition of ArcherDX, where she served as Executive Vice President of Quality, Regulatory and Business Strategy. Sandra brings more than 25 years of experience in health outcomes, diagnostic, medical device and therapy development, having successfully guided more than 20 drugs, biologics and medical devices through domestic and international regulatory approval. Prior to joining ArcherDX, Sandra served as chief executive officer of GenEngine, a pharmaceutical and diagnostic product industry consulting practice. In addition. Sandra was responsible for building the health outcomes function for Baxter Healthcare/Caremark, leading the research and clinical biomarker functions, including personalized medicine at Eli Lilly and Company and served as the Chief Scientific Officer for Arrogen. Sandra holds a Bachelor of Science degree from Indiana University, Bloomington, a Master of Science degree from Columbia University, New York and a Ph.D. in Medical and Molecular Genetics from Indiana University, Indianapolis.

Robbie Evans , , , Chief Strategy Officer

Robbie leads strategic and operational analysis at Invitae, combining the business intelligence, decision modeling, and internal consultancy functions to enable effective decision making through the intersection of data analysis, critical thinking, and shared expertise. Robbie joined Invitae as a pre-commercial startup and has led an array of operating, software, and commercial efforts as Invitae has grown into an industry leader. Prior to joining Invitae, Robbie served in strategic planning for the San Francisco 49ers and in portfolio management for Stanford University's endowment management fund. A cancer survivor since the age of 22, Robbie joined Invitae with a desire to create a better, smarter, more personalized healthcare system. Robbie holds a B.A. in economics from Stanford University.

Desarie French , , , Chief Talent Officer

Desarie leads Talent Operations at Invitae in sourcing, recruiting, developing, training and retaining the company’s most valuable asset: our team. Prior to joining Invitae, Desarie served in various human resources leadership roles at Thermo Fisher Scientific, serving multiple functions, businesses and regions with expertise in talent acquisition, M&A and regional leadership roles. Desarie holds a B.A. in Business from Cal Poly, SLO and an M.S. in Employee Relations from Penn State. Desarie has spent most of her career in the healthcare/biotech industry with a passion for building great teams in organizations committed to creating a healthier tomorrow.

Alex Furman , , , Co-Founder, Culture Tsar and Head of People Analytics

Alex is a co-founder of Invitae specializing in people analytics and organizational development to drive the company's efforts to create a collaborative company culture that delivers innovation at scale. As part of the team that has propelled Invitae from early stage startup to a leader transforming the industry, Alex championed the company’s culture. Its proprietary talent management system, ORG1, was Alex's brainchild, built on his recognition that the way people are evaluated and promoted should and could be based on data-informed decision making via a people analytics platform. Prior to Invitae, Alex led software engineering at Navigenics, overseeing the design and implementation of the company’s technology platform. Alex spent prior years developing automated trading systems and financial planning software for several companies. Alex is also on the Board of Directors for EcoShift Development, a firm offering a comprehensive range of sustainability planning services related to global climate change and environmental conservation. A born and bred programmer, Alex wrote his first piece of code at age nine.

Shelly Guyer , , , Chief Financial Officer

Shelly leads Invitae’s finance team, helping to position the company as an innovator in the dynamic and ever-changing genomics market. Shelly has extensive experience building and leading strong financial functions as a senior executive and leader in life sciences, as well as domain expertise from years as an investment banker and venture capitalist. Prior to Invitae, Shelly was the chief financial officer at Veracyte, Inc., a genomic diagnostics company, and earlier served as CFO and EVP of finance and administration at iRhythm Technologies, Inc., a digital healthcare company redefining the clinical diagnosis of cardiac arrhythmias. She began her business career at Hambrecht & Quist and later J.P. Morgan Securities, where she held various positions, including principal of healthcare banking for the West Coast, leading financings for a variety of large and small cap life science companies. Shelly holds an AB from Princeton University and an MBA from the Haas School of Business, University of California, Berkeley.

Ken Knight , , , Chief Operating Officer

Ken oversees growth and scale across all of Invitae’s operations, with a focus on innovation on behalf of patients and clients. Prior to joining Invitae, Ken served as Vice President at, Inc., a multinational and diversified technology company, leading Amazon's Transportation Services, Global Delivery Services, and Global Fulfillment operations and human resources. Before his time at Amazon, Ken served as General Manager of the Material Handling and Underground business division at Caterpillar Inc. and in various senior executive capacities at General Motors Company, including leadership of global manufacturing engineering, advanced technology development, and operations. Ken holds a B.S. in Electrical Engineering from the Georgia Institute of Technology and a MBA from the Massachusetts Institute of Technology Sloan School of Management.

Robert Nussbaum , , M.D. , , Chief Medical Officer

Dr. Nussbaum leads Invitae’s medical team, which is driving forward the science and practice of medical genetics and improving clinical understanding of how to use genetics to improve patient care.. Prior to joining Invitae, he was chief of the Division of Genomic Medicine at UCSF Health where he also held leadership roles in the Cancer Genetics and Prevention Program, and the Program in Cardiovascular Genetics, as well as serving as a member of the UCSF Institute for Human Genetics. Earlier, Dr. Nussbaum was chief of the Genetic Disease Research Branch of the National Human Genome Research Institute, one of the National Institutes of Health. He is a member of the Institute of Medicine and a fellow at the American Academy of Arts and Sciences. Dr. Nussbaum is a board-certified internist and medical geneticist who holds a B.S. in Applied Mathematics from Harvard College and an M.D. from Harvard Medical School in the Harvard-MIT joint program in Health Sciences and Technology. He completed his residency in internal medicine at Barnes-Jewish Hospital and a fellowship in medical genetics at the Baylor College of Medicine.

Eric Olivares , , Ph.D. , , Chief Science Officer

Eric leads research and development efforts around corporate strategy, commercial needs and future technology development. As part of the team that has propelled Invitae from early stage startup to a leader transforming the industry, Eric has developed next-generation sequencing workflows for over a decade at both tool suppliers and instrument manufacturers, dedicated to expanding access to the highest quality, most robust, and lowest cost genetic tests in the world. He joined Locus Development, an early-stage startup that later merged with Invitae, to lead the molecular biology R&D group. Eric holds a Ph.D. in Genetics from Stanford University and a B.S. in Genetics from University of California, Davis.

Michelle Sommargren , , Ph.D. , , President, Medical Genetics

Michelle leads product development efforts at Invitae, with a focus on bringing forward products designed to make genetic information accessible and actionable to both patients and clinicians. She is an expert in leading large, cross-functional teams and is constantly striving to improve our product development pipelines by routing out inefficiencies to enable faster delivery of Invitae’s industry-leading comprehensive testing menu as well as a more intuitive, simple customer experience. As part of the team that propelled Invitae from an early stage startup to a leader transforming the industry, Michelle previously led program management at Invitae and was a development scientist at Locus Development, an early stage genetic analysis startup that later merged with Invitae. Earlier in her career, Michelle worked as a research scientist and technical lead in the CA Safe Cosmetics Program at the California Department of Public Health and as a scientist at Navigenics. Michelle holds a Ph.D. in Neurobiology & Behavior and M.P.H. in Environmental & Occupational Health Sciences, both from the University of Washington, and a B.A. in Molecular & Cellular Biology from the University of California, Berkeley.

Josh Stahl , , , Chief Science Officer, Oncology

Josh leads research and development efforts for Invitae's oncology team, having joined Invitae through the acquisition of ArcherDX, where he served as Chief Operating Officer and Chief Scientific Officer. Josh joined ArcherDX in 2013, guiding the company’s product portfolio first as director of NGS research and development and scientific operations and later as vice president of research and development. In 2016, Josh expanded his role, assuming responsibility for ArcherDX’s operational functions. Prior to joining Archer, Josh was a scientist at Thermo Fisher Scientific, where he worked on the company’s gene modulation portfolio developing siRNA and shRNA NGS-based screening methods. Josh holds a bachelor’s degree in Biochemistry and Molecular Biology from West Virginia University. He attended graduate school at the University of Colorado, Boulder where he earned both a master’s degree in biochemistry and a Master of Business Administration degree in entrepreneurship.

Katherine Stueland , , , Chief Commercial Officer

Katherine is passionate about how genetic information can help everyone make more informed healthcare decisions through testing and the power of a network that connects patients, clinicians, researchers, and patient communities to better inform what a patient can do with their diagnosis. With a relentless focus on opening up access for patients, she leads Invitae’s global commercial teams, including sales, international, biopharma partnerships, the direct ordering channel for patients, marketing, customer service, new market development, and communications/investor relations. Katherine cares deeply about the importance of broadening research to diverse patient populations to advance science and patient care for everyone. She previously led Invitae’s communications and investor relations team. Prior to joining Invitae, Katherine worked with management teams of biopharma companies, including serving as vice president of communications and investor relations at Dendreon, the first company to bring an immuno-oncology product to market. Katherine holds a B.S. in English Language and Literature from Miami University in Ohio.

Karthik Suri , , , Chief Digital Officer

Karthik leads Invitae’s Data and Digital platform strategy, delivery, GTM, security, and operations. He also has responsibilities in Information Security and Information Technology to drive cyber security and productivity across the organization. Previously, Karthik served as chief operating officer at GE Digital and COO for GE’s Industrial IOT & Data Platform. In addition, he has held leadership roles in platform technology companies including PayPal, eBay, Magento, Yahoo!, and Barclays following his early career at GE. In addition, Karthik serves on the Steering Committee of the World Economic Forum’s Digital Platform & Ecosystems group and also on the board of directors for Junior Achievement of Northern California. He holds a Bachelor’s in Mechanical Engineering and a Masters in Chemistry from BITS, Pilani, India; a Masters in Industrial & Systems Engineering from The Ohio State University; and a dual MBA from Columbia Business School and University of California, Berkeley, Haas School of Business.

Layton Wedgeworth , , , Chief Technology Officer

Layton leads software engineering efforts focused on using software to make affordable genetic testing accessible at scale. As part of the team that has propelled Invitae from early stage startup to a leader transforming the industry, Layton has played a pivotal role in developing many of the publicly and internally facing software systems that have served more than a million patients since. Outside of Invitae, Layton was an early engineer at many now well-known consumer startups, including Path, Instacart, and Hipcamp. Layton was drawn to Invitae's mission after watching one of his closest friends battle through a diagnostic odyssey while battling a serious health issue, which was ultimately diagnosed through genetic testing.

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *

Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103